Information Provided By:
Fly News Breaks for July 13, 2015
ANAC
Jul 13, 2015 | 11:15 EDT
Wedbush raised Anacor's price target to $190 from $85 citing the positive release of top-line data from its two Phase III trials showing crisaborole met the primary and secondary endpoints in patients with mild-to-moderate atopic dermatitis. The firm sees little regulatory risk for crisaborole and sees sales reaching $2B in 2020. The firm has an Outperform rating on shares.
News For ANAC From the Last 2 Days
There are no results for your query ANAC
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.